Clinical Trials Browser

Phase 1 × tislelizumab × 1 year × Clear all

NCT06427941 2026-04-17

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT06233942 2026-04-15

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06596473 2026-04-15

A Study of BG-C477 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06422520 2026-04-06

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06848465 2026-04-03

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Phase 1 Recruiting

Advanced Non-small Cell Lung Cancer

NCT05768932 2026-03-27

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

BreastGastrointestinalOther hematologic neoplasm

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT05981703 2026-03-19

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06487858 2026-03-18

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06585488 2026-03-18

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Phase 1 Recruiting

GastrointestinalOther solid neoplasmThoracic

Metastatic Solid Tumors

NCT06540066 2026-03-16

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

Neoplasm Metastasis

NCT05935098 2026-03-13

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

Phase 1 Terminated

Neoplasm Metastasis

NCT07453875 2026-03-06

TRIUNITE06

Phase 1 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05526924 2026-03-04

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04649385 2026-02-20

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07414836 2026-02-17

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

Phase 1 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07353294 2026-01-20

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Phase 1 Not yet recruiting

Lymphatic Metastasis

NCT07348107 2026-01-16

ATARI-PDAC

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT07317609 2026-01-05

Endosurgery-02

Phase 1 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Phase 1 Completed

Head and Neck Neoplasms

NCT04294160 2025-12-24

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Phase 1 Terminated

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT07059299 2025-12-19

NeoTISLEGA

Phase 1 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06349837 2025-12-17

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumor

NCT05547321 2025-11-25

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Sarcoma, Stomach Neoplasms

NCT05789069 2025-11-21

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT04215978 2025-10-03

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Completed

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05904496 2025-09-16

A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT04047862 2025-08-22

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1 Completed

446 enrolled 49 charts

Other solid neoplasm

Locally Advanced and Metastatic Solid Tumors

NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Phase 1 Not yet recruiting

Urinary Bladder Neoplasms, Neoplasms

NCT07077369 2025-07-22

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

Phase 1 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06969612 2025-06-06

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Phase 1 Terminated

DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

NCT05494762 2025-05-01

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumor

NCT05167071 2025-04-27

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Phase 1 Active not recruiting

Neuroendocrine Tumors